Result of AGM

Arix Bioscience

17/05/2018 12:29

RNS Number : 4558O

Arix Bioscience Plc

17 May 2018

 

 

 

Arix Bioscience Plc

 

Results of Annual General Meeting

 

LONDON, 17 May, 2018: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or the "Company"), a global healthcare and life science company supporting medical innovation, announces that its Annual General Meeting (the "Meeting") was held on Thursday 17 May 2018 at 11am (BST). At the Meeting, the ordinary and special resolutions set out in the Notice of the Annual General Meeting dated 20 April 2018 (the "Notice of AGM"), were proposed and passed by way of a poll. Resolutions 1 to 15 were passed as ordinary resolutions. Resolutions 16 to 19 were passed as special resolutions.

 

Full details of the poll results are set out below and will also be available on the Company's website www.arixbioscience.com.

 

No
RESOLUTION
VOTES FOR
%
VOTES AGAINST
%
TOTAL VOTES
% of ISC VOTED
VOTES WITHHELD
1
To receive the Directors' report and the accounts for the Company for the year ended 31 December 2017
56,584,402
100.00
0
0.00
56,584,402
41.99%
0
2
To approved the Directors' Remuneration Report for the year ended 31 December 2017
50,988,886
90.12
5,591,495
9.88
56,580,381
41.98%
4,020
3
To re‐elect Dr Joseph Anderson as a Director
56,584,402
100.00
0
0.00
56,584,402
41.99%
0
4
To re‐elect Professor Sir Christoher Evans as a Director
56,584,402
100.00
0
0.00
56,584,402
41.99%
0
5
To re‐elect Dr Franz Humer as a Director
51,655,214
91.29
4,929,188
8.71
56,584,402
41.99%
0
6
To re‐elect Lord John Hutton of Furness as a Director
54,810,619
96.87
1,773,783
3.13
56,584,402
41.99%
0
7
To re‐elect Professor Trevor Jones as a Director
56,584,402
100.00
0
0.00
56,584,402
41.99%
0
8
To re‐elect Jonathan Peacock as a Director
54,526,217
96.36
2,058,185
3.64
56,584,402
41.99%
0
9
To re‐elect James Rawlingson as a Director
56,584,402
100.00
0
0.00
56,584,402
41.99%
0
10
To re‐elect David U'Prichard as a Director
55,183,865
97.53
1,399,000
2.47
56,582,865
41.99%
1,537
11
To elect Meghan FitzGerald as a Director
56,584,402
100.00
0
0.00
56,584,402
41.99%
0
12
To elect Giles Kerr as a Director
56,582,865
100.00
0
0.00
56,582,865
41.99%
1,537
13
To re‐appoint PwC LLP as auditors of the Company
55,185,402
97.53
1,399,000
2.47
56,584,402
41.99%
0
14
To authorise the Audit & Risk Committee of the Company to fix the remuneration of the auditors
56,584,402
100.00
0
0.00
56,584,402
41.99%
0
15
To authorise the Directors to allot shares
55,618,631
100.00
2,198
0.00
55,620,829
41.27%
963,573
16
To authorise the Directors to disapply statutory pre‐ emption rights in respect of 5% of the Company's issued share capital
53,013,611
95.32
2,605,020
4.68
55,618,631
41.27%
965,771
17
To authorise the Directors to disapply statutory pre‐ emption rights in respect of an additional 5% of the Company's issued share capital
51,614,611
92.80
4,004,020
7.20
55,618,631
41.27%
965,771
18
To authorise the Company to buy back shares
54,215,987
97.48
1,403,929
2.52
55,619,916
41.27%
964,486
19
To authorise the Directors to call a general meeting other than an annual general meeting on not less than 14 clear days' notice
56,581,832
100.00
2,570
0.00
56,584,402
41.99%
0

 

 

Notes:

1.      Any proxy arrangement which gave discretion to the Chairman has been included in the "for" totals.

2.      A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution.

3.      The number of voting shares in issue at 6:00 p.m. on 15 May 2018 was 134,764,018 (the "Share Capital"). The Company does not hold any shares in treasury.

 

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at www.hemscott.com/nsm.do

 

ENDS

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

Robert Lyne, Company Secretary

+44 (0) 20 7290 1055

 

Charlotte Parry, Investor Relations Manager

+44 (0)20 7290 1072

charlotte@arixbioscience.com

 

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

+44 (0)20 3709 5700

arix@consilium-comms.com

 

 

About Arix Bioscience plc

 

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

 

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

 

For further information, please visit www.arixbioscience.com

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

RAGFKODBDBKDOPD